• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

C30/C75二硫键对昂科纳酶生物学特性的贡献。

Contribution of the C30/C75 disulfide bond to the biological properties of onconase.

作者信息

Torrent Gerard, Benito Antoni, Castro Jessica, Ribó Marc, Vilanova Maria

机构信息

Laboratori d'Enginyeria de Proteïnes, Departament de Biologia, Facultat de Ciències, Universitat de Girona, Campus de Montilivi s/n, E-17071 Girona, Spain.

出版信息

Biol Chem. 2008 Aug;389(8):1127-36. doi: 10.1515/BC.2008.114.

DOI:10.1515/BC.2008.114
PMID:18979636
Abstract

Onconase, a member of the pancreatic type ribonuclease family, is currently used as a chemotherapeutic agent for the treatment of different types of cancer. It is widely accepted that one of the properties that renders this enzyme cytotoxic is its ability to evade the cytosolic ribonuclease inhibitor (RI). In the present work, we produced and characterized an onconase variant that lacks the disulfide bond C30/C75. This variant mimics the stable unfolding intermediate des(30-75) produced in the reductive unfolding pathway of onconase. We found that the reduction of the C30/C75 disulfide bond does not significantly alter the cytotoxic properties of onconase, although the variant possesses a notably reduced conformational stability. Interestingly, both its catalytic activity and its ability to evade RI are comparable to wild-type onconase under mild reductive conditions in which the three disulfide containing intermediate des(30-75) is present. These results suggest that the C30/C75 disulfide bond could easily be reduced under physiological redox conditions.

摘要

癌抑素是胰腺型核糖核酸酶家族的一员,目前用作治疗不同类型癌症的化疗药物。人们普遍认为,使这种酶具有细胞毒性的特性之一是其逃避胞质核糖核酸酶抑制剂(RI)的能力。在本研究中,我们制备并表征了一种缺乏二硫键C30/C75的癌抑素变体。该变体模拟了癌抑素还原解折叠途径中产生的稳定解折叠中间体des(30-75)。我们发现,尽管该变体的构象稳定性显著降低,但C30/C75二硫键的还原并未显著改变癌抑素的细胞毒性特性。有趣的是,在存在含三个二硫键的中间体des(30-75)的温和还原条件下,其催化活性和逃避RI的能力与野生型癌抑素相当。这些结果表明,在生理氧化还原条件下,C30/C75二硫键很容易被还原。

相似文献

1
Contribution of the C30/C75 disulfide bond to the biological properties of onconase.C30/C75二硫键对昂科纳酶生物学特性的贡献。
Biol Chem. 2008 Aug;389(8):1127-36. doi: 10.1515/BC.2008.114.
2
Dissimilarity in the reductive unfolding pathways of two ribonuclease homologues.两种核糖核酸酶同系物还原展开途径的差异
J Mol Biol. 2004 May 7;338(4):795-809. doi: 10.1016/j.jmb.2004.03.014.
3
Characterization of the fast-forming intermediate, des [30-75], in the reductive unfolding of onconase.在抗癌酶还原解折叠过程中快速形成的中间体des [30-75]的表征
Biochemistry. 2004 Mar 23;43(11):3246-54. doi: 10.1021/bi036215d.
4
Impact of the C-terminal disulfide bond on the folding and stability of onconase.C 端二硫键对依诺酶折叠和稳定性的影响。
Chembiochem. 2010 May 3;11(7):978-86. doi: 10.1002/cbic.200900773.
5
Role of the N terminus in RNase A homologues: differences in catalytic activity, ribonuclease inhibitor interaction and cytotoxicity.N 端在核糖核酸酶 A 同源物中的作用:催化活性、核糖核酸酶抑制剂相互作用及细胞毒性的差异
J Mol Biol. 1996 Apr 19;257(5):992-1007. doi: 10.1006/jmbi.1996.0218.
6
A synapomorphic disulfide bond is critical for the conformational stability and cytotoxicity of an amphibian ribonuclease.一个共源同形二硫键对于一种两栖类核糖核酸酶的构象稳定性和细胞毒性至关重要。
FEBS Lett. 2000 Jul 21;477(3):203-7. doi: 10.1016/s0014-5793(00)01804-4.
7
Dissimilarity in the oxidative folding of onconase and ribonuclease A, two structural homologues.癌酶与核糖核酸酶A(两种结构同源物)氧化折叠的差异
Protein Eng Des Sel. 2008 Apr;21(4):223-31. doi: 10.1093/protein/gzm093. Epub 2008 Jan 31.
8
Contribution of chain termini to the conformational stability and biological activity of onconase.链末端对癌酶构象稳定性和生物活性的贡献。
Biochemistry. 2001 Aug 7;40(31):9097-103. doi: 10.1021/bi010741s.
9
Contribution of active-site residues to the function of onconase, a ribonuclease with antitumoral activity.活性位点残基对癌酶(一种具有抗肿瘤活性的核糖核酸酶)功能的贡献。
Biochemistry. 2003 Oct 7;42(39):11443-50. doi: 10.1021/bi035147s.
10
Interaction of onconase with the human ribonuclease inhibitor protein.癌蛙酶与人核糖核酸酶抑制蛋白的相互作用。
Biochem Biophys Res Commun. 2008 Dec 12;377(2):512-514. doi: 10.1016/j.bbrc.2008.10.032. Epub 2008 Oct 16.

引用本文的文献

1
A Humanized Anti-CD22-Onconase Antibody-Drug Conjugate Mediates Highly Potent Destruction of Targeted Tumor Cells.一种人源化抗 CD22-奥曲肽抗体药物偶联物介导高效靶向肿瘤细胞的杀伤作用。
J Immunol Res. 2015;2015:561814. doi: 10.1155/2015/561814. Epub 2015 Oct 28.
2
Ribonucleases as potential modalities in anticancer therapy.核糖核酸酶作为抗癌疗法的潜在手段。
Eur J Pharmacol. 2009 Dec 25;625(1-3):181-9. doi: 10.1016/j.ejphar.2009.06.067. Epub 2009 Oct 14.